tbuckley/cabot-search huggingface dataset:
Replicative Senescence-Associated Gene Expression Changes In Human MSPCs Independent of Genomic Variations
Authors: Katharina Schallmoser, Christina Bartmann, Eva Rohde, Simone Bork, Christian Guelly, Anna C. Obenauf, Andreas Reinisch, Patrick Horn, Anthony D. Ho, Werner Linkesch, Gerhard Lanzer, Wolfgang Wagner, Dirk Strunk
Journal: Blood (2010)
Interim safety analysis of a phase II trial combining trastuzumab and NeuVax, a HER2-targeted peptide vaccine, to prevent breast cancer recurrence in HER2 low expression
Authors: D.O. Jackson, K.M. Peace, D.F. Hale, T.J. Vreeland, G. Choy, B. Nejadnik, J.M. Greene, E.J. Schneble, J.S. Berry, A.F. Trappey, M.O. Hardin, G.T. Clifton, G.S. Herbert, E. Mittendorf, J.P. Holmes, G.E. Peoples
Journal: Annals of Oncology (2016)
Mechanism Research of Magnetic Nanoparticle Fe3O4 and 5-Bromotetrandrine On Reversal of Multidrug Resistance in K562/A02 Leukemic Cells.
Authors: Bao-An Chen, Wei-Wei Wu, Jian Cheng, Feng Gao, Wen-Lin Xu, Chong Gao, Jia-Hua Ding, Xin-Chen Sun, Cui-Rong Xu, Ning-Na Chen, Guo-Hua Xia, Xue-Mei Wang, Wen-Ji Chen, Li-Jie Liu, Xiao-Mao Li
Journal: Blood (2009)
P05.02 The Chk1 inhibitor SAR-020106 abrogates the irradiation-induced G2 arrest and enhances the effect of irradiation on the clonogenic survival of human p53-mutant glioblastoma cells
Authors: I. Patties, M. Frisman, E. Kendzia, F. Menzel, F. Gaunitz, R. Kortmann, A. Glasow
Journal: Neuro-Oncology (2016)

within 12 weeks after drug interruption and steroids treatment associated or not with intravenous immunoglobulins.CONCLUSIONS: Neurological complications reported with immune checkpoint inhibitors are non-specific and pleomorphic, the most common being meningitis, radiculoneuropathy and myasthenic syndromes.In almost all cases, the outcome was favorable after drug interruption and steroid treatment.As suggested for other irAEs, nAEs may be associated with a clinical benefit and could be indicative for tumor-specific immune activation.
EVI1, a Gene Frequently Involved in Myelodysplastic Syndrome, Causes an Erythroid Dysplasia in a Mouse Model with Conditional Transgene Expression.
Authors: Eric van den Akker, Dominik Spensberger, Antoinette Beijen, Kirsten van Lom, Claudia Erpelinck, Ruud Delwel
Journal: Blood (2004)
Azacitidine in Relapsed and Refractory AML: Efficacy for Patients Relapsing As MDS Post AML
Authors: Sarah Ivanoff, Emilie Lemasle, Berengere Gruson, Lavinia Merlusca, Amandine Charbonnier, Anne Parcelier, Gandhi Damaj, Bruno Royer, Jean Pierre Marolleau
Journal: Blood (2012)
SGI-110, a Novel Second Generation Potent DNA Methylation Inhibitor, In Development for the Treatment of MDS and AML. Preclinical Safety, Pharmacokinetics, and DNA Methylation Results of a Low Volume Subcutaneous (SC) Formulation
Authors: Jason Scholl, Rajashree Joshi-Hangal, Roger Inloes, Chongtie Shi, Pietro Taverna, Gavin S. Choy, Sanjeev Redkar, Mohammad Azab
Journal: Blood (2010)
Updated, expanded analysis with next generation sequencing (NGS) of biliary tract cancer confirms association between tumor somatic variants and chemotherapy resistance
Authors: D.H. Ahn, D. Catenacci, C.W. Ahn, A. Jain, R.K. Kelley, A.G. Bocobo, R. Rendak, S. Mikhail, C. Wu, R.T. Shroff, M. Borad, J.L. Chen, M. Javle, T. Bekaii-Saab
Journal: Annals of Oncology (2016)
Clinical Practice Guidelines
Authors: Sheldon Greenfield
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The antitumor activity of lenvatinib (LEN) in combination with everolimus (EVE) in human renal cell carcinoma (RCC) xenograft models is dependent on VEGFR and FGFR signaling
Authors: T. Kimura, Y. Adachi, M. Matsuki, A. Yamaguchi, Y. Ozawa, K. Okamoto, K. Mitsuhashi, T. Hoshi, O. Tohyama, K. Tai, M. Ogo, J. Matsui, Y. Funahashi
Journal: Annals of Oncology (2016)
Molecular definition of a metastatic lung cancer state reveals a targetable CD109–Janus kinase–Stat axis
Authors: Chen-Hua Chuang, Peyton G Greenside, Zoë N Rogers, Jennifer J Brady, Dian Yang, Rosanna K Ma, Deborah R Caswell, Shin-Heng Chiou, Aidan F Winters, Barbara M Grüner, Gokul Ramaswami, Andrew L Spencley, Kimberly E Kopecky, Leanne C Sayles, E Alejandro Sweet-Cordero, Jin Billy Li, Anshul Kundaje, Monte M Winslow
Journal: Nature Medicine (2017)
Italian observational study on T-DM1 in HER2 positive advanced breast cancer patients: real world effectiveness and safety
Authors: A. Fabi, D. Alesini, M. De Laurentiis, E. Valle, D. Santini, K. Cannita, L. Carbognin, M. Ciccarese, G. Arpino, V. Leonardi, F. Montemurro, N. La Verde, D.G. Generali, G. Scandurra, M. Russillo, I. Paris, A.M. D'Ottavio, G. Filippelli, S. Stani, D. Giannarelli, F. Cognetti
Journal: Annals of Oncology (2016)
Characterization of the Immune Response to Canine Factor IX Following AAV-Mediated Intravascular Gene Delivery to Skeletal Muscle in Hemophilia B Dogs.
Authors: Daniel J. Hui, Federico Mingozzi, Denise E. Sabatino, Stephanie McCorquodale, Aaron Dillow, Timothy C. Nichols, Valder R. Arruda, Katherine A. High
Journal: Blood (2005)
QLIF-24. ASSESSING THE BENEFICIAL IMPACTS OF THE NEURO-ONCOLOGY HOSPITALIST PRACTICE MODEL: PILOT RUN AT UC IRVINE
Authors: Xiao-Tang Kong, Dan Fu
Journal: Neuro-Oncology (2016)

Current practice model of neuro-oncology focuses on seeing neuro-oncology patients in clinic and spending limited time in the inpatient setting. A mid-level provider or a trainee usually rounds on the neuro-onc patients and briefly discusses the rounds with a neuro-oncologist during, before, or after busy clinic. Alternatively, the primary service has a quick discussion with the neuro-oncologist, who is also seeing patients in a busy clinic or doing research. The benefit of the current practice model is increased outpatient efficiency and productivity. However, without the specialized neuro-oncology expertise in the inpatient service, the primary teams sometimes conduct extensive unnecessary clinical testing or discharge the patients without addressing significant medical and neurological comorbidities. Believing the inpatient management of neuro-onc patients is equally important as outpatient neuro-onc patient care, the UCI neuro-oncology program initiated a neuro-oncology hospitalist practice model in 2015. By being actively involved in the care of the neuro-onc patients in hospital, a neuro-oncology hospitalist helps identify tumor versus non-tumor cases, triage surgery versus non-surgery cases, and assists post-surgical care. The neuro-oncology hospitalist almost always spends sufficient time with the patients and their families to explain the potential diagnosis, treatment plan, and roles of the involved medical teams, to prepare the patients and families for their stressful first clinic visit. In addition, the neuro-oncology hospitalist guides the discharge plan, attends all family meetings, discusses the goal of care, communicates among the cross functional teams, orders inpatient chemotherapy and evaluates the adverse effects. This new inpatient neuro-oncology hospitalist practice model has shown benefits for our neuro-onc patients and the hospital: it shortens the length of stay, increases DRG score, satisfaction of the patient, family, and the variety of the primary and other consulting services. Benefits of this model over a longer period shall be further investigated.
Long-Term Complete Molecular Remissions in Untreated Symptomatic Follicular Lymphoma Treated with Rituximab as Single Agent and in Combination with Interferon-alpha-2a: Analysis of Minimal Residual Disease in the Randomized Phase II Study M39035.
Authors: Jesper Jurlander, Christian Geisler, Hans Hagberg, Harald Holte, Tuula Lehtinen, Eva Kimby
Journal: Blood (2004)
QLIF-03. MUTANT IDH1 PROMOTES TUMOR-ASSOCIATED EPILEPSY IN GLIOMA PATIENTS
Authors: Hao Chen, Jonathon Judkins, Farhad Ghamsari, Pamela Lein, Craig Horbinski
Journal: Neuro-Oncology (2016)

Seizures are a major quality-of-life issue for patients with infiltrative gliomas. Over 50% will experience at least one seizure during the course of their disease, and over 30% will develop tumor-associated epilepsy (TAE), defined as multiple seizures. Lower-grade gliomas are more likely to cause TAE than glioblastomas (GBMs), though the reasons for this are unclear. Grade II-III gliomas are far more likely to contain mutations in isocitrate dehydrogenase 1 (IDH1mut) than grade IV GBMs. The product of IDH1mut, D-2-hydroxyglutarate (D2HG), is released by tumor cells into the microenvironment. D2HG is structurally similar to a powerful excitatory neurotransmitter, glutamate, which triggers neuronal depolarization by opening NMDA channels. Therefore, we hypothesized that IDH1mut increases seizure risk through the activity of D2HG on neurons within and around the tumor. In 3 cohorts from separate institutions (total N=712), seizures were a part of the presenting symptoms in 18-34% of IDH1 wild-type (IDH1wt) patients and in 59-74% of IDH1mut patients (P<0.0001). Multiple logistic regression modeling, including 1p/19q codeletion and temporal lobe location, showed that IDH1mut was the only significant independent correlate with seizures in all 3 cohorts (OR=2.5-10.4). Although clinical presentation with seizures has previously been reported as a predictor of longer survival, Cox proportional hazards modeling suggest that this is due to its link with IDH1mut (RR=0.78 for seizures, P=0.39; RR=0.027 for IDH1mut, P<0.001). Exogenous D2HG increased the firing rate of cultured rat cortical neurons in a dose-dependent manner, up to 374% in 10 mM D2HG. This was completely blocked by the selective NMDA antagonist, AP5. These data show, for the first time, a direct mechanism of action by D2HG on neurons, supported by data from 3 large cohorts of glioma patients. This has translational implications for the personalized management of TAE, as targeted IDH1mut inhibitors may improve antiepileptic therapy in IDH1mut patients.
Study on expression of androgen-receptor splice variant-7 (AR-V7) in preoperative chemotherapy for breast cancer
Authors: Yuka Asano, Shinichiro Kashiwagi, Wataru Goto, Kento Kurata, Tamami Morisaki, Satoru Noda, Tsutomu Takashima, Naoyoshi Onoda, Masahiko Ohsawa, Masaichi Ohira, Kosei Hirakawa
Journal: Annals of Oncology (2016)
Compliance, capacity, and quality in colonoscopy screening for CRC: A novel solution.
Authors: S. C. Lloyd
Journal: Journal of Clinical Oncology (2011)

357 Background: CRC is predominately preventable with high quality colonoscopy screenings. Unfortunately, less than half of Americans are “up-to-date.” When referred by primary care providers, less than half complete the process. We proposed to include the primary care provider (PCP) in a novel training program to extend skills from sigmoidoscopy to full colonoscopy in a “mentored and monitored” model. We know that quality in colonoscopy can vary widely (ten fold within a single 12-man group). The protective benefits of colonoscopy reflect the thoroughness of the removal of polyps. Unfortunately, the ACS projections for 2010 predict an increase of 4,400 deaths from CRC over 2009, an 8% rise! Furthermore the death rate for African American men has RISEN 28% since 1960. We are loosing a battle for which we posses the tools to win. To achieve victory we must successfully address all three factors: compliance, capacity and quality. Methods: Thirty primary care physicians in two states (SC, FL) were recruited. We measured compliance rates within the practice before and after enrollment. We further evaluated quality of the colonoscopies as reflected in completion, yield and complications. Results: Compliance more than doubled (38% to 84%). As a compliance enhancement tool, the results were outstanding. The evaluation of quality then became of paramount importance. The gross completion rate was 98.3%, the adenoma detection rate (reflecting polyp yield) was 38%. In over 20,000 cases there were only 5 perforations, substantially below published rates. The quality was consistently at the level of experienced conscientious gastroenterologists. The details of the training program and the use of the “two-man” colonoscopy technique have been reviewed elsewhere (MEDICAL CARE, Aug 2010). Conclusions: If replicated nationally, this model has the potential for saving 25,000 lives annually. The participation of the patient's PCP is a powerful influence for improved compliance. The availability of an “expert” for mentoring and monitoring results in outstanding and consistent quality. The model has the potential to dramatically enhance compliance simultaneously increasing capacity while maintaining outstanding quality. No significant financial relationships to disclose.
Incidence and distribution of HER2-positive gastric and gastroesophageal junction (GEJ) adenocarinomas in British Columbia (BC).
Authors: H. J. Lim, F. Aubin, C. K. Kollmannsberger, D. Huntsman, B. Carter, C. Zhou, R. Woods, S. Gill
Journal: Journal of Clinical Oncology (2011)

91 Background: HER2-positive rates have been reported as 20% of GC and 34% in GEJ adenocarcinoma in a recent global phase III trial with trastuzumab and chemotherapy. This study examines the incidence and distribution HER2-positive GC and GEJ adenocarcinomas in the province of BC. Methods: Formalin fixed embedded tissue from patients (pts) with resected gastric or GEJ adenocarcinoma from 2004-2007 were identified retrospectively through the BC Cancer Agency registry and prospectively for pts with a new diagnosis of advanced disease. Biopsies and resection samples were analyzed via previously validated methods IHC (Ventana 4B5 antibody), FISH (Eurovision probes) and SISH (Ventana probes). IHC scores of 3 were considered positive, 2 were cequivocal and 0 or 1 were negative. A 10% cut-off was used to determine positive samples. Equivocal staining was considered positive via FISH or SISH. A ratio of &gt; 2.0 was considered amplified for FISH and SISH. P values were calculated using a logistic regression model with HER2 positive as the endpoint. Results: Of the 87 samples, 64 (74%) were gastric and 23 (26%) GEJ. Overall, HER2 was positive 20% (IHC), 18% (FISH) and 18% (SISH). 13% of cases tested IHC 3+ while 24% tested IHC 2+. In equivocal IHC 2+ cases, 7% were considered positive by FISH. Positivity rates were higher for GEJ (26%, 22% and 17%) vs. gastric (8%, 11% and 9%) via IHC (p = 0.02), but did not significantly differ by FISH (p = 0.19), or SISH (p = 0.30) respectively. The majority of positive cases were intestinal type vs. other (diffuse type or mixed) 25% vs. 0% IHC p = 0.0002, 25% vs. 3% FISH p = 0.001, 20% vs. 3% SISH p = 0.006. The positivity rates were similar with biopsy vs resection specimens (12% vs. 16% IHC p = 0.64, 12% vs. 21% FISH p = 0.30, 12% vs. 10%, SISH p = 0.88). Conclusions: The rates of HER2-positive disease in a Western population based study were similar to the ToGA study. HER 2 positivity was associated with cancers arising in the GEJ and of intestinal type. The frequency of positivity was similar for testing by biopsy versus resection specimens. This study is ongoing and updated results will be reported. No significant financial relationships to disclose.
Poster Session 4: Hepatitis B Therapy
Journal: Hepatology (2014)

Background: Long-term nucleoside/tide analogue (NA) treatment suppresses serum HBV DNA to undetectable levels in a majority of patients.We aimed to investigate the effect of longterm NA on the suppression of covalently closed circular DNA (cccDNA) and intrahepatic HBV DNA (ihHBV-DNA).Methods: We recruited 40 patients (median age 44.2 years, range 24.3-63.2) who had been on continuous long-term (5 -10 years) NA.All patients had 3 liver biopsies: at baseline, after 1 year of treatment and at the last follow-up.Serum HBV DNA and HBsAg were measured by the COBAS TaqMan HBV Test and the Elecsys HBsAg II Assay, respectively (both Roche Diagnostics).ihHBV-DNA and cccDNA were assayed by real-time PCR, with lower limits of detection of 0.001 and 0.005 copies/cell, respectively.Results: The median duration of treatment was 10.5 years (range: 6.0 -11.9 years).At baseline, 13 patients had 100mg lamivudine, 11 had 600mg telbivudine, 9 had 0.5mg entecavir, 4 had 30mg clevudine, and 3 had 10mg adefovir.At the last follow up, these patients were on 0.5-1.0mgentecavir (n=23), 600mg telbivudine (n=9), 10mg adefovir (n=4), 300mg tenofovir (n=2), or combination therapy of lamivudine plus adefovir/tenofovir (n=2).Histology of the third biopsy showed complete resolution of interface hepatitis in 60% of patients with the remainder showing mild-to-moderate activity.Persistent immunoreactivity for HBsAg was found in 80%, the mean number of hepatocytes positive for HBsAg being 10.4% (range 1-80%).All but 1 (2.5%) was immunoreactive for HBcAg.At baseline, the median serum HBV DNA, HBsAg, ihHBV-DNA and cccDNA levels were 6.84 logIU/ mL, 3.38 logIU/mL, 286 copies/cell, and 7.3 copies/cell, respectively.At the time of the last biopsies, 36 (90%) patients had undetectable serum HBV DNA (<20 IU/mL), all but one patient still had detectable HBsAg (median: 2.74 logIU/mL), all had detectable ihHBV-DNA (median: 0.4 copies/cell), but 18 (45%) patients had undetectable cccDNA.There was a trend of reduction of HBsAg, ihHBV-DNA and cccDNA levels from baseline to 1 year to last follow-up (all p<0.0001).The median log drop of HBsAg at last biopsy was 0.55 logIU/mL.The median percentage reductions of HBsAg, ihHBV-DNA and cccDNA at last biopsies were 71.46%, 99.85% and 99.89%, respectively.Conclusions: Long-term NA treatment significantly reduced cccDNA and ihDNA.45% of patients had undetectable cccDNA, although small amount of ihHBV-DNA were still detectable in all patients.Integrated HBV DNA may be a possible source of detectable ihHBV-DNA and HBsAg.Continuous long-term NA therapy can reduce cccDNA to undetectable levels, suggesting a possible end-point of treatment.
Impact of Acute GVHD on Immune Reconstitution after Cord Blood Transplantation in Adult.
Authors: Tokiko Nagamura-Inoue, Satoshi Takahashi, Jun Ooi, Akira Tomonari, Toru Iseki, Kaoru Uchimaru, Fumitaka Nagamura, Nobuhiro Ohno, Kashiya Takasugi, Munechika Futami, Michihiro Uchiyama, Yasushi Soda, Taka-aki Konuma, Shin Nakayama, Mika Shioya, Nobukazu Watanabe, Shigetaka Asano, Arinobu Tojo, Tsuneo A. Takahashi
Journal: Blood (2004)
IMST-58. MODULATING THE MYELOID COMPARTMENT TO POTENTIATE ANTI-PD1 MEDIATED IMMUNOTHERAPY AGAINST GLIOBLASTOMA
Authors: Tomas Garzon Muvdi, Debebe Theodros, Maria Carrera-Haro, Eileen Kim, Christopher Jackson, Andrew Luksik, Betty Tyler, Henry Brem, Drew Padroll, Michael Lim
Journal: Neuro-Oncology (2016)

Combinatorial immunotherapy targeting multiple immune compartments to treat glioblastoma (GBM) is an attractive tool due to the complex immune microenvironment. Activation of toll-like receptor 3 (TLR3) is known to stimulate antigen presenting cells (APC) and dendritic cells (DC) and secretion of inflammatory cytokines (interferon gamma, IL-6, and TNF-alpha). Through augmentation of antigen presentation with PD1 blockade we sought to enhance the anti-tumor immune response in a GBM model. Under ACUC approval, C57BL6 mice underwent implantation of GL261 cells in the left striatum stereotactically. The presence of tumor was confirmed by bioluminescence at day 7. Mice were randomized to 4 groups: Control, PD1, Poly IC, and PD1+Poly IC treatment. Survival was assessed using log-rank analysis and described using Kaplan-Meier curves. Immune response at the tumor and systemically was assessed with flow cytometry (FC) and analyzed with ANOVA and student’s T-test. PD1+PolyIC treatment of mice resulted in 80% long-term survival of mice and improved survival compared to control group and PD1 or PolyIC groups alone(p<0.0001). When the tumor infiltrating immune cells were analyzed with FC we found significantly increased effector T-cells and decreased naïve T-cells in PD1+PolyIC group. Interestingly, memory T-cells increased in deep cervical lymph nodes and in the spleen. Activated DCs and macrophages were increased in the spleen with PD1+PolyIC treatment. Also, in the PD1+PolyIC group migratory DCs were decreased in the brain and increased in the lymph node and spleen. Poly IC causes increased ingression and enhances antigen presentation of myeloid cells in GBM to potentiate anti-PD-1 mediated anti-tumor immune response.
Infographic: 2016 Consensus statement on return to sport from the First World Congress in Sports Physical Therapy, Bern
Authors: Clare L Ardern, Philip Glasgow, Anthony G Schneiders, Erik Witvrouw, Benjamin Clarsen, Ann MJ Cools, Boris Gojanovic, Steffan Griffin, Karim Khan, Håvard Moksnes, Stephen Mutch, Nicola Phillips, Guus Reurink, Robin Sadler, Karin Gravare Silbernagel, Kristian Thorborg, Arnlaug Wangensteen, Kevin Wilk, Mario Bizzini
Journal: British Journal of Sports Medicine (2017)

Infographic: 2016 Consensus statement on return to sport from the First World Congress in Sports Physical Therapy, Bern
CASCADE study: pronounced decline in treatment efficacy through the metastatic life of breast cancer patients
Authors: L. Paz De Arias, P. Garía. Teijido, S. Servitja, A. Santaballa, J. García, Y. Plata Fernández, I. Garau, J. Florian, I. Chacón, Jdela Haba, P. Zamora, L. Orcajo Rincon, J. Rodríguez-Villanueva, M.Á Seguí, E. Martínez
Journal: Annals of Oncology (2016)